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creates new forms of power with specific characteristics: the need of 
transparent subjects, the participation of patients to the power that 
aims to take control on their own body, and the growing porosity 
between the private and public sectors. First applied to the analysis 
of sexuality, the concept of biopower is nowadays highly relevant 
to analyze this new turn in medicine practices that involve the full 
cooperation and transparency of patients.
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Multiple sclerosis—new chances?
F. Curtin*
GeNeuro SA, Geneva, Switzerland
Summary: The treatment of multiple sclerosis as an autoimmune 
disorder has benefited for several years from the progresses of bio-
therapeutics. Since the mid-1990s, interferon beta has been proposed 
as a valuable treatment for certain MS patients due to its immu-
nomodulator properties, followed shortly after by the registration 
of the polypeptide glatiramer acetate. More recently, monoclonal 
antibodies have been developed to target selective components of the 
immune response and provide a selective immunosuppression that 
could treat the disease with an acceptable safety profile. Natalizumab 
was the first of these monoclonal antibodies, and other monoclonal 
antibodies such as rituximab or alemtuzumab, originally developed 
in oncology, have since been repositioned for autoimmune disor-
ders such as MS. However, these molecules, which are very selective 
in their targets, often do not appear so favorable during develop-
ment, and their safety profile could significantly limit their use. More 
recently, the development of monoclonal antibodies has refocused 
more on targeting proteins that play critical roles in the pathophysiol-
ogy of MS, notably on the specific processes of neurotoxicity: these 
antibodies are now in early clinical development and may bring new 
avenues in the treatment of MS.
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safety inforMation today and how  
can we iMprove toMorrow?
A. Czarnecki*
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Kingdom
Summary: Ever since “modern” pharmacovigilance started in the 
early 1980s, it has gone through changes of various pace introduced 
by new concepts (eg, CIOMS I-V), development of science and meth-
odologies (eg, pharmcoepidemiology), technology (eg, databases), or 
regulatory requirements (eg, risk management, new legislation). Over 
the period of time, methods of data collection and analysis became 
easier, which is helpful, taking into account the fast-growing world’s 
population. However, everyday general medical practice did not 
change much despite great progress in sciences. Large safety data are 
accessible from organized databases in regulatory bodies, industry, 
medical insurance, and other organizations, facilitating their analysis 
and aggregate evaluation, but in many situations, actions are still 
triggered by the assessment of causal associations based on medical 
judgment performed on individual cases or case reports. The future 
of pharmacovigilance should be based on well-thought-through risk 
management combined with risk minimization activities, which will 
reflect preceding appropriate benefit/risk assessment. This can be 
delivered by adequate training in clinical pharmacology, which will 
include good prescribing practices and the development of regulatory 
science either within clinical pharmacology or as a separate discipline. 
In addition, the broad understanding of important safety information 
collected and assessed from population data and in large databases 
should grow and facilitate data-driven scientific decision making.
Clinical pharmacology has an important role at present and in the 
future by providing curricula for HCPs across the world, teaching 
appropriate prescribing, risk management/minimization concepts, 
and contributing to the increase in protection of public health and 
individual patient safety by being much more prominent in the HCP 
training and clinical practice.
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Summary: Every day, European poisons centers (PC) assess poison-
ing risks of thousands of exposures to toxic agents and give advice 
for best-practice medical treatment, triggered by telephone calls from 
medical staff, patients, or caregivers. PC are continuously registering 
all exposure cases in local databases and are analyzing these data to 
detect or verify unusual poisoning events (often involving several or 
many patients) and trends of poisoning.
By this method of toxicovigilance, for example, the Swiss PC 
detected series of unexpected breathing disorders caused by regular 
intended use of 1 of 3 waterproofing spray products in 2003 and, 
more recently in 2012, the GIZ-Nord Poisons Centre in Germany dis-
covered a Ciguatera poisoning series (14 patients) generated by con-
taminated seafood (Red Snapper) purchased in local supermarkets. In 
some of these events, the toxic products identified were removed from 
shops within hours, after notifications of PCs to retail, competent 
regional, or national authorities, prevented many more poisonings.
In the past, unexpected poisoning risks that might have been caused 
by rare exposures and very rare notification to PC may have been 
missed if only single cases were notified to PC, and the cases could not 
been validated with sufficient quality. Today, networks of PC facili-
tate exchange of observations, case reports, and related toxicologic 
knowledge to rapidly confirm new or unusual poisoning risks. With 
help of conveniently new communication tools, several PC networks 
have been founded or intensified in Europe in the last decade. The 
European Association of Poisons Centres and Clinical Toxicologists 
forms the most powerful and Europe-wide expert network.
In 2011, the Public Health Project “Alert System for Health 
Threats” (ASHT, sponsored by the European Commission and the 7 
project partner organizations) had designed and tested a surveillance 
system that can collect a vast number of exposure cases reported to 
PC in real time. This system facilitates the timely concomitant analy-
sis of all cases submitted to detect unusual and hidden poisoning risk 
in a more sensitive way in the near future.
In conclusion, toxicosurveillance of population poisoning risks, 
enabled by PC’s toxicovigilance, has played an important role in 
detecting unexpected poisonings, especially poisonings caused by 
intended use of unsafe products in the past, and will play an even 
more important role in the future powered by rapidly reacting PC 
networks.
Disclosure of Interest: None declared.
the relevance of clinical workplace 
learning and assessMent in cp&t
T. Dornan*
Educational Development and Research, Maastricht University, 
Maastricht, the Netherlands
clinical therapeutics
e116 volume 35 number 8s
Summary: Educational reforms over a century ago established a the-
ory to practice undergraduate medical curriculum design, in which 
“theory” equated with biomedical science. It is remarkable that a 
theory of professional knowledge that is so old has been so little 
challenged. We continue to assume that mastery of a rather limited 
canon of knowledge will lead inductively to practical competence and 
are surprised and disappointed when it does not. Donald Schön has 
written about the tension between the “high ground” of the universi-
ties and the “swampy lowlands” of practice. Gradually, the swampy 
lowlands have gained scholarly credibility, and a tension is becoming 
apparent between the competence that is needed to be an effective 
practitioner and the competencies that are taught in universities. 
Yet, there is a common desire that medicine should be a scholarly 
discipline. This presentation explores how theory and practice can 
best be integrated in the education of safe and effective practitioners. 
It draws on theories of training design and observational research 
into how medical students prepare for transition to residency. It aims 
to answer the question “how can medical students best prepare to 
prescribe effectively after starting their careers as doctors”?
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genetics of treatMent response  
in depression
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Summary: Up to 60% of depressed patients do not respond com-
pletely to antidepressants (ADs) and up to 30% do not respond at 
all. Genetic factors contribute for ~50% of the AD response. During 
recent years, the possible influence of a set of candidate genes as 
genetic predictors of AD response efficacy was investigated by us 
and others. They include the cytochrome P-450 superfamily, the 
P-glycoprotein (ABCB1), the tryptophan hydroxylase, the catechol-
O-methyltransferase, the monoamine oxidase A, the serotonin trans-
porter (5-HTTLPR), the norepinephrine transporter, the dopamine 
transporter, variants in the 5-hydroxytryptamine receptors (5-HT1A, 
5-HT2A, 5-HT3A, 5-HT3B, and 5-HT6), adrenoreceptor β -1 and 
α -2, the dopamine receptors (D2), the G protein β 3 subunit, the 
corticotropin-releasing hormone receptors (CRHR1 and CRHR2), 
the glucocorticoid receptors, the c-AMP response-element binding, 
and the brain-derived neurotrophic factor. Marginal associations 
were reported for angiotensin I–converting enzyme, circadian loco-
motor output cycles kaput protein, glutamatergic system, nitric oxide 
synthase, and interleukin 1-β gene. In conclusion, gene variants seem 
to influence human behavior, liability to disorders, and treatment 
response. Nonetheless, gene × environment interactions have been 
hypothesized to modulate several of these effects.
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ethics and privacy of biobanks
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Summary: The advances in genetics and informatics have stimu-
lated research involving biobanks. Research using samples and data 
involves privacy risks. Identifiability and its degrees have implications 
on determining the risk/benefit ratio of a research project. Although 
the need to protect confidentiality and to put in place security meas-
ures is widely recognized, terminological confusion and philosophical 
differences dominate the ethical and legal discussion about confi-
dentiality of data and samples. Different mechanisms, such as cod-
ing or anonymization, influence not only privacy risks of those who 
supplied the biological samples but also determine whether it will 
be possible to communicate the results of any genetic analysis back 
to the research participants. Moreover, it is generally admitted that 
donors have the right to opt out of a biobank. This means that they 
may ask for destruction or unlinked anonymization of samples and 
data. Both can only be carried out if a link is kept between the donors 
and their samples and data.
In this presentation, different strategies of anonymization and 
coding will be described and ethical and legal arguments in favor 
and against them will be discussed, based on the framework of inter-
national ethical guidance and human rights implemented in Europe.
Disclosure of Interest: None declared.
encepp: strengthening Methodology, 
transparency and independence
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Summary: The European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP), coordi-
nated by the European Medicines Agency, has seen rapid growth 
in recent years and now accounts for > 170 partner organizations, 
including research centers, therapeutic networks, and data source 
owners. The increase in pharmacoepidemiology research via net-
works such as ENCePP is a clear trend to make best use of available 
data and expertise, through the conduct of high-quality, independ-
ent, and transparent studies focusing on safety and on benefit/risk. 
Through ENCePP, there is an enhanced capacity to plan and per-
form postauthorization studies that are essential to the monitoring 
of safety and efficacy of medicines throughout the product lifecycle.
In addition to increasing capacity for important observational 
research as requested by regulatory authorities and providing a read-
ily available pool of pharmacoepidemiology expertise, ENCePP has 
been instrumental in developing tools that translate guiding princi-
ples into research practice. The network’s outputs include a Code 
of Conduct, a guide on methodologic research standards, and a 
Checklist for Study Protocols. These are all cited in the recently pub-
lished module VIII of Good Vigilance Practice on PASS. A database 
of studies developed through ENCePP is currently serving as the EU 
PAS Register, where companies register their PASS in compliance 
with the provisions on transparency in the new PhV legislation. 
The EU PAS Register welcomes registration of studies conducted 
worldwide.
Current opportunities for the network include sourcing of sus-
tainable funding for the partner organizations and existing networks 
involved, perceived barriers to sharing of data for studies applying 
for an ENCePP Study Seal, and extension of the network to research 
centers outside of the EU. Overcoming these challenges is important 
to the continued success of the network.
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Mediator (benfluorex), a french and 
worldwide public health disaster
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Summary: Mediator® (benfluorex), a French and worldwide public 
health disaster
Irène Frachon, MD
CHU de la Cavale Blanche, Groupe HTAP de Bretagne 
Occidentale, Dept de médecine interne et pneumologie, EA 3878, 
IFR 148, Brest, France.
Benfluorex (brand names Mediator®, Mediaxal® , Lipascor®; 
drug company Servier) was marketed in France and worldwide until 
2009. This marketing authorization was held while the  compounds 
